fbpx

Study: Metastatic Brain Tumor Patients Under 50 Show Improved Survival Rates with Stereotactic Radiosurgery

A recent study published in the official journal of the American Society for Radiation Oncology (ASTRO) found that cancer patients with limited brain metastases who are under 50 years old could benefit from stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT). 

The study analyzed patient data from the three largest randomized clinical trials of SRS and WBRT conducted to-date. For patients under the age of 50 who received SRS alone, survival was improved by 13 percentage points when compared to those patients under the age of 50 who received both SRS and WBRT.

Lead author of the study Dr. Arjun Sahgal explained, “We expected to see a survival advantage favoring combined therapy of SRS and WBRT. However, these data clearly demonstrate the benefit for SRS alone to improve survival for our younger patients with limited brain metastases.”

Austin CyberKnife’s clinical team has extensive experience treating primary brain tumors and brain metastases with CyberKnife® stereotactic radiosurgery. If interested in learning whether you or a loved one may be a candidate for CyberKnife treatment, contact us at (512) 324-8060 to receive more information and learn about our treatment process

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.